Cipla gets EIR from USFDA for API facility at Virgonagar

MUMBAI, Sept 23:Pharma Major, Cipla said that its API manufacturing facility in Virgonagar, Bengaluru has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA , indicating closure of the inspection.
The Facility was inspected from July 15-19, 2019,company said in a filing with BSE.
(UNI)